University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer

GOTHENBURG, Sweden - Cellectricon, a leading provider of cell-based screening solutions for research and drug discovery, today announced its collaboration with University of Lodz, Poland. Under the agreement University of Lodz invests in Cellaxess(R)HT, the world’s first system for high throughput transfection enabling reagent-free delivery of any genetic material to cells.

To view the Multimedia News Release, please click:

www.prnewswire.com/mnr/cellectricon/39261/

“We are excited about the collaboration with Cellectricon and believe the Cellaxess(R)HT system will greatly advance our efforts in our research program focusing on cell biology and molecular genetics of clinically relevant genes related to cancer treatment,” says Prof. Grzegorz Bartosz, head of Department of Molecular Biophysics at the University of Lodz. “Genomic screening is a rapidly-evolving field and the need is very significant for a technology enabling high transfection efficiency and viability in biologically relevant cell types. Cellaxess(R)HT will allow us to undertake ambitious expression and silencing screening projects that would have been both economically and practically unfeasible with conventional instrumentation.” Purchase of the Cellaxess(R)HT system by the University of Lodz was made possible by funding from the Innovative Economy Operational Programme of the Republic of Poland, supported in part by the European Union through the European Regional Development Fund.

“Adoption of Cellaxess(R)HT by the University of Lodz into their research program demonstrates the capabilities of this state-of-the-art system designed for genomic research and screening. Cellectricon has developed the system in close collaboration with leading research groups and leading pharmaceutical companies to meet the increasing demand for a generic technology capable of true high throughput transfection,” says Jonas Ohlsson, CEO at Cellectricon. “Cellaxess(R)HT will significantly impact this research field since it enables reagent-free high throughput delivery of any genetic material to biologically relevant cell types.”

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon’s products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in preclinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput transfection in genomic screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

Contact Details: Jonas Ohlsson, CEO Phone: +46(0)709-73-47-92, E-mail: jonas.ohlsson@cellectricon.com Susanne Fagerlund, VP Marketing & Communications Phone: +46(0)31-760-35-15, E-mail: susanne.fagerlund@cellectricon.com

Source: Cellectricon AB

Contact Details: Jonas Ohlsson, CEO, Phone: +46(0)709-73-47-92, E-mail: jonas.ohlsson at cellectricon.com; Susanne Fagerlund, VP Marketing & Communications, Phone: +46(0)31-760-35-15, E-mail: susanne.fagerlund at cellectricon.com